When the disease no longer responds to these methods, then cytotoxic agents may be tried, but not before. It may seem unreasonable to use these agents only at this stage, but their possible benefits are associated with more serious sideeffects than the other methods of treatment referred to. It is possible that they may be more useful in combination with hormone therapy or prophylactically after surgery, but the assessment of such methods requires carefully controlled groups, and they should never be 'tried out' on occasional patients unless the more orthodox methods have proved useless.
Conclusions
This paper is intended to convey two ideas: first, that cytotoxic drugs and other agents can be of very great benefit to patients with malignant disease but, secondly, that they can be dangerous if used incorrectly. They may produce serious side-effects, they may prevent adequate treatment by other methods, and when ambiguous results are published they encourage others to adopt the same viewpoint. Of course, there is nothing to stop any registered medical practitioner from using these potentially dangerous agents, without any specialized knowledge of cancer or any previous training in their use. When cytotoxic drugs are misused, it is probably because of the following chain of events: (1) The doctor, perhaps not fully aware of the natural history of the disease in his patient, feels excessively pessimistic about the chance of cure or palliation by conventional methods.
(2) The doctor is human and wishes to help the patient. (3) Chemotherapy is a harmless word; obviously, if a doctor is qualified to use penicillin, he is qualified to use a cancer chemotherapy agent. (4) The patient is human and if he knows the nature of his illness or has symptoms, he naturally wants something done. (5) Relatives are also human and want actionpreferably with the newest agent. And so, another course of a cytotoxic agent is given. Under these circumstances, it is difficult to judge who receives the greatest palliationthe patient, his relatives, or the doctor. ( Chemotherapy in malignant disease is still a developing subject. The agents now available are not very effective. Each agent must be uscd in a different way for the treatment of different conditions, and it is probable that we are not using the drugs we already have in the best possible way. It is possible also that for each particular condition there may be more than one effective way of using a drug, but there are so many variables to consider that it is very difficult to work out the best method except by trial and error. In a broad way we can consider the use and abuse of chemotherapy only in those conditions in which there is general agreement that chemotherapy is effective.
Dr D A G Galton
Before discussing particular situations in the treatment of leukemia and lymphoma I should like to make a general point. Once one accepts a patient suffering from malignant disease for chemotherapy one accepts that patient for the rest of his life and must be responsible for the management of his disease, from that time until he dies. It is very unfortunate that even now patients are sometimes treated by chemotherapy and are considerably improved, but are then sent away with no proper arrangements for follow up or adequate maintenance therapy. If they do not die at home they usually return to hospital in an advanced stage of relapse, and it may then be very difficult to treat them effectively again. I shall consider some critical aspects of the management of two acute and two chronic malignant conditions. In acute leukaemia in childhood, and in lymphoblastic lymphosarcoma presenting with massive mediastinal involvement, it is essential to induce remission rapidly; in the Section ofMedicine treatment of chronic granulocytic leukoemia with busulphan, and in the management of massive serous effusions associated with the more chronic forms of generalized follicular or diffuse lymphosarcoma there is more time to consider a policy of treatment and how to apply it.
Acute Leukwmia
It is now certain that the life of children suffering from acute lymphoblastic leuklemia is prolonged by the methods available today. These include what are often referred to as specific antileuklemia agents, namely mercaptopurine, methotrexate, vincristine, cyclophosphamide and prednisone, and also the proper use of blood transfusion, platelet transfusion and antibiotics. With good routine care, more than one-half of the children now survive over a year, and about onefifth survive for two years. If properly managed the children should lead practically normal lives throughout the whole of their illness until their terminal phase. Not many years ago some paediatricians doubted whether there was any justification for treating children who were bound to relapse within a few months and whose lives, though prolonged, might be expected to be a misery to them and to their parents. However, this misery is largely avoidable, and the nihilistic attitude is no longer defensible; I have yet to meet parents who have regretted that their children were treated. Most have been grateful that they had their children for the extra time. So there is no longer a case for denying treatment to children with lymphoblastic leukaemia, but if the clinical course is to be smooth a great deal of attention to every detail of management is necessary.
Induction of remission:
The aim of conventional chemotherapy is to reduce the total number of blast cells in the body to the smallest number consistent with safety. This requires the administration of one or more drugs at the highest dosage possible without the production of toxic sideeffects. When the bone marrow has been largely cleared of blast cells, the hlmopoietic cells regenerate rapidly, and normal bone-marrow function is restored. Having induced the remission it is necessary to maintain it.
Patients usually present in an advanced state of bone-marrow failure, and vigorous supportive therapy is required to relieve anwmia, to arrest hemorrhage resulting from thrombocytopenia, and to treat infections resulting from neutropenia. It is generally accepted now that the administration of a combination of drugs is the best way of inducing rapid remission in the highest percentage of cases. Prednisone is combined with mercaptopurine, methotrexate or vincristine. A favoured combination now is that of prednisone and vincristine: prednisone is given orally at a daily dose of 40 mg per square metre of body surface and vincristine is given weekly, intravenously, each dose being 2 mg per square metre of body surface. The prednisone dosage is tailed off after the end of the third week and three injections of vincristine are given. Remission should be in rapid progress by the end of the second week, with rapidly rising reticulocyte, platelet and neutrophil counts, usually in that order. In patients who respond favourably the bone marrow should be free of blast cells to ordinary inspection, and should show active regeneration from four to six weeks after the start of treatment when maintenance therapy is begun. It is true that prednisone alone may be as effective in inducing remission as it is when used in combination with one of the other drugs, but the frequency of remission is somewhat lower. Mercaptopurine alone is also frequently effective in inducing remission, but the rate of induction is far too slow to be practicable because it is imperative to relieve the state of bone-marrow failure as rapidly as possible. One reason for preferring the combination of prednisone and vincristine for the induction of remission is that neither drug is suitable for long-term therapy, because of its special side-effects. On the other hand methotrexate, mercaptopurine and cyclophosphamide are the drugs of choice for maintenance therapy. If one of these drugs is used for induction there is, theoretically at any rate, a slight risk that surviving blast cells may be resistant, so that the drug used for induction would no longer be an effective agent for maintenance therapy.
Maintenance therapy: The aim of maintenance therapy is to suppress the proliferation of the residual blast cells surviving after the induction of remission. In this way bone-marrow function is preserved. Maintenance therapy is effective as long as the cells are sensitive to the drug used. Once resistant blast cells appear the agent in use at that time can no longer be used. There is no general agreement on the most effective way of applying methotrexate, mercaptopurine and cyclophosphamide in a programme of maintenance therapy. Here I want only to draw attention to the results of a comparative trial of two dosage schedules of methotrexate administration in the maintenance of remissions induced by the combination of prednisone and vincristine.
This trial was carried out by the Leukemia Study Group B in the United States of America (Selawry et al. 1965) . These workers showed that the maintenance of remission was far more effective when methotrexate was administered at high dosage twice weekly than when the drug was administered in the conventional way at low 1269 73 1270 Proceedings ofthe Royal Society ofMedicine daily dosage by mouth. The high dose regime involved the use of intramuscular methotrexate at a dose of 30 mg per square metre of body surface twice weekly. The drug may also be administered by mouth in one single dose. In practice, unfortunately, this regime requires much closer supervision because severe ulceration of the inside of the lips readily occurs, and it is often necessary to omit one or two doses until the ulcers have healed, and to reduce the dose administered when treatment is resumed. However, the study clearly showed that the precise details of the dosage schedule for methotrexate are of critical importance. There can be little doubt that the dosage schedule is of equal importance in the case of the other drugs also. A trial carried out by the Leukemia Study Group A showed that cyclophosphamide administered daily by mouth was more effective than when high-dose intermittent administration intravenously was used.
Detection of relapse: Almost always the bone marrow becomes heavily infiltrated by blast cells several weeks before there is any evidence of clinical bone-marrow failure as shown by fall in the hemoglobin, neutrophil or platelet values, or before any blast cells are seen in the peripheral blood. It is not uncommon to find the bone marrow almost wholly replaced by blast cells when the peripheral blood is still entirely normal. By allowing a child to relapse clinically, or by relying on the falling peripheral blood values as indicators of relapse, one is exposing the child to the grave hazards of bone-marrow failure. The only way to detect relapse before bone-marrow function has become impaired, and in the absence of blast cells in the peripheral blood, is to examine the bone marrow at regular intervals. Here one has to compromise between the longest time compatible with obtaining the necessary information and the shortest time consistent with avoidance of inconvenience to the child and his parents. There is no room for misplaced sentiment. One must be kind but one must be right as well. Properly performed bone-marrow aspiration inflicts little discomfort. If the information it yields is foregone, and the child is allowed to go into bone-marrow failure, he may have to endure intolerable suffering that could have been avoided.
Bone marrow aspiration in children needs careful planning to ensure that nothing goes wrong, and that neither child nor mother is upset.
They must not be kept waiting, the child must be properly sedated, and many children below 5 years of age do better with a general anaesthetic. Eight-to-ten-week intervals have usually proved adequate. Physical examination, full blood count including hvmoglobin, platelet count, total and differential leucocyte count should be made every three to four weeks. In this way it should be possible to maintain the child clinically well almost throughout the course of its disease.
MeningealLeuka?mia
At least one-quarter of all children suffering from acute lymphoblastic leukemia develop meningeal leukemia; because its effects, once established, are likely to be irreversible, it is important to detect it early (Haghbin & Zuelzer 1965) . At every follow-up visit careful attention must be paid to minimal symptoms suggestive of raised intracranial pressure, and the optic fundi must be regularly inspected for early papillcedema. Meningeal leukmemia may become evident during hmematological remission. The condition responds in most cases to methotrexate administered intrathecally and even recurrences may respond to the same treatment. The important practical point is to treat the condition at the earliest possible stage, so here again the emphasis is on a meticulous follow-up routine. Some workers advise regular lumbar punctures to detect the earliest appearance of leukemic cells in the cerebrospinal fluid, and prophylactic intrathecal injections of methotrexate have also been advocated; the value of these additional rather drastic procedures has not been established. Not all patients respond to intrathecal methotrexate, and radiation therapy to the skull still has a place in the management of meningeal leukemia.
Fever in Acute Leukwmia
Patients who are severely leucopenic as a result of bone-marrow failure from any cause are highly susceptible to infections. When the disease is known not to be leukamia it is the rule to search diligently for the cause of the fever, but all too often in the case of a leukemic patient the fever is assumed to be 'leukaemic' and no effort is made to search for infection. One should assume that fever in leukaemic patients is due to infection until proved otherwise, and although it must be admitted that a cause is not always found, it often is, and even when no cause is found the fever will often settle on empirical antibiotic therapy. It is particularly important to treat infections adequately when remission is being induced, because even when the bone-marrow failure has been relieved by adequate antileukwmic therapy, the patient may have inherited a legacy of intractable infection left over from the phase of severe neutropenia. It is tragic that patients with leukemia so often succumb to infection with treatment-resistant organisms including Pseudomonas aeruginosa and viruses. One disastrous effect of major infection during the induction of remission is that it suppresses the regeneration of the bone marrow with the result that a period of marrow hypoplasia ensues. The bone marrow is found to be hypoplastic but there is no evidence of active leukemia. When the infection has been overcome by appropriate treatment marrow regeneration proceeds apace until restoration of function has occurred. It is difficult to know when to begin maintenance therapy in these patients because the use of cytotoxic agents during the hypoplastic phase may lower the resistance to the infection by reducing the already inadequate neutrophil response, and may also delay the onset of marrow regeneration. On the other hand, the longer antileukwemic therapy is delayed the more chance the residual blast cells have of proliferating to numbers sufficiently large to prevent bonemarrow regeneration. The decision that has to be made is therefore critical, but the patient's future will depend on striking the balance between overcoming the infection and not unduly delaying the resumption of antileukmmic therapy.
Mediastinal Lymphosarcoma and Lymphoblastic Leukamia
Dyspnoea of acute onset is a not uncommon presenting symptom of lymphosarcoma in children and young adults, and is due to the presence of a massive and rapidly growing mediastinal tumour. Sometimes peripheral lymphadenopathy is also present and if a node is excised for biopsy the appearance is that of diffuse poorly differentiated lymphosarcoma. This presentation is commonly regarded as an indication for urgent radiotherapy. In most cases rapid symptomatic relief will follow and the mediastinal shadow will shrink rapidly. Unfortunately, acute lymphoblastic leukaemia may develop during the course of radiation therapy or shortly after its completion. Review of the blood counts and the blood films in these cases often reveals either the presence of a few blast cells in the blood at the time of presentation or evidence of bone marrow failure, suggesting that the bone marrow was already filling up with blast cells at the time of presentation. It is therefore very important to investigate these patients hwmatologically at the time of presentation, because the same principles of management apply to them as to patients with more typical acute lymphoblastic leukemia. These enormous mediastinal masses will shrink just as rapidly when treated with prednisone and vincristine or prednisone combined with one of the other antileukwmic agents, or even prednisone alone, as with radiotherapy. In addition, chemotherapy will clear the bone marrow of blast cells; this is not so in the case of radiotherapy, when the proliferation of untreated blast cells in the bone marrow leads to bone-marrow failure which may be beyond the possibility of effective chemotherapy.
I now pass to a consideration of two chronic conditions in which chemotherapy may be conducted in a more leisurely way, chronic granulocytic leukemia and lymphosarcoma complicated by serous effusions.
Chronic Granulocytic Leukwmia: Use ofBusulphan
In chronic granulocytic leukimia the great majority of patients present with symptoms, and as they are almost always rapidly relieved after the start of busulphan therapy there is usually little point in deferring treatment. In this disease no attempt is made to restore the bone marrow to a normal condition. When the spleen has regressed and the peripheral blood picture has returned to normal, the bone marrow is still grossly hypercellular and aspirated fragments are devoid of fat. To attempt to continue chemotherapy beyond this is dangerous because irreversible marrow hypoplasia is easily induced. A few patients are very sensitive to busulphan. The end point of the initial course of therapy is therefore critical, and it is recommended that treatment is stopped when the total leucocyte count has fallen to between 15,000 and 20,000 per c.mm. This usually takes between three and six months at a daily dosage of 4 mg or 0 065 mg per kg of body weight, whichever is less. A not uncommon mistake is to become impatient after four to six weeks because the leucocyte count has fallen apparently very little. Such patients are often said to be refractory to chemotherapy and are unnecessarily referred for radiotherapy. If radiotherapy is applied in the ordinary way to the spleen the resultant fall in the leucocyte count is often unexpectedly great and such patients easily go into extreme bone-marrow hypoplasia which may be irreversible. There are occasional patients who require higher doses of busulphan but special vigilance is then required.
Busulphan is such a toxic drug that the followup of patients receiving maintenance therapy requires meticulous attention to the leucocyte and platelet counts, and adjustment of the daily dose is a delicate matter. I find it impossible to manage this disease, or indeed any disease in which marrow-depressant therapy is used, without keeping a hematological chart. One can inspect the previous trends of the h2moglobin concentration, the platelet and leucocyte counts,. and from these trends it is much easier to decide at each visit the daily dose of busulphan necessary to preserve or to restore favourable trends. Trouble may ariseifdifferent doctors see the patient at each visit. In one tragic case prescriptions for busulphan at 4 mg daily had been written every month for four months, apparently with no reference to the blood counts, which showed progressive thrombocytopenia and leucopenia. The bone 76 marrow became totally aplastic, and heroic but unsuccessful efforts were made to keep this young woman alive in the hope that marrow regeneration would occur. If a working chart had been kept as part of the discipline of management, the dangerous trends of the platelet and neutrophil counts would have been apparent at an early stage, and the drug might have been discontinued in time. A useful precaution, which, if observed, would almost certainly have saved another life lost as a result of overdosage, is to prescribe only sufficient tablets to last until the next appointment.
Busulphan is still the treatment of choice for chronic granulocytic leukemia, and I recently saw a patient of Dr L G Israels's in Winnipeg who had taken busulphan continuously for thirteen years and whose remission was still maintained. However, a small minority of patients develop a curious wasting syndrome with some features ofAddison's disease after prolonged busulphan therapy (Kyle et al. 1961 ). Some of these patients also develop dyspnoea, cough, and low grade fever which progress and may lead to extreme respiratory distress , Koss et al. 1965 , Smalley & Wall 1966 . This is due to alveolar capillary block caused by exudation of fibrin into the alveoli with subsequent organization. It is possible that some of these patients might improve if the condition were detected earlier and busulphan replaced by some other drug such as mercaptopurine or demecolcine (Colcemid). But one of my patients developed the Addison-like syndrome and pulmonary failure four months after the cessation of busulphan therapy which he had had for the previous two years. Fortunately these complications are excessively rare and should not contraindicate busulphan therapy.
Lymphosarcoma Complicated by Serous Effusions
Generalized lymphosarcoma complicated by massive serous effusions often involves both pleural cavities as well as the peritoneal cavity. Usually this situation is associated with a very different type of disease from that discussed above in connexion with mediastinal lymphosarcoma. Here the pathology is that of well-differentiated lymphocytic lymphoma, more often follicular than diffuse. It is usually associated with massive generalized lymph-node enlargement, sometimes with hepatosplenomegaly, and with gross aedema. Here the most effective treatment is probably prednisone or its equivalent, at a daily oral dose of 40 mg. This induces a rapid diuresis with resorption of the effusions, and subsidence of the cedema. The effect is probably due to the rapid shrinkage of the enlarged lymph nodes and release of the blocked lymphatic drainage. Even chylous effusions may respond. Intracavitary injections of nitrogen mustard, other alkylating agents, or radioactive gold are likely to be ineffective. The steroid therapy should be replaced after six or eight weeks by an alkylating agent such as chlorambucil or cyclophosphamide, the administration of which may have to be continued indefinitely to prevent relapse. It is essential here, as in all other types of case to which I have referred, to maintain continuity of follow up and adequate suppressive therapy. One of these patients who had been grossly cedematous for many months and was quite incapacitated had been successfully treated with prednisone and chlorambucil, but was lost to follow-up for two and a half years. She had received no further therapy, had relapsed shortly afterwards, and once more became bedridden. She has again responded to treatment, but it is depressing that more than two years of her life have been wasted. Part of the blame in this case is due to the still too prevalent pessimism associated with malignant disease. Patients with malignant disease are expected to relapse, and all too often when they do so little or no effort is made to discover what might be done for them.
Mr G Westbury (Westminster Hospital, London)

Intra-arterial Administration of Cytotoxic Drugs
The treatment of localized malignant disease by cytotoxic agents administered into the appropriate artery was first reported -in 1950 (Klopp et al.) . Nitrogen mustard (HN2) was given by intermittent injection into the carotid arteries of a group of patients with tumours of the head and neck. Lesions such as carcinoma of the mouth, ordinarily untreatable by chemotherapy, responded dramatically to doses of a conventional order but delivered in a very high local concentra-
